Radiotherapy-Associated Atrial Fibrillation

NCT ID: NCT05927246

Last Updated: 2023-07-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-01

Study Completion Date

2023-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Radiotherapy associated Atrial Fibrillation (RADAF) is an observational study to evaluate onset time and frequency of atrial fibrillation in patients with thoracic malignancies and breast cancer.

Each patient will have 12 lead ECG prior, and daily during radiotherapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Collected data will be truly anonymised and individuals will no longer identifiable, and than evaluated for occurrence of atrial fibrillation.

Inclusing Criteria:

1. Patients with radiotherapy for thoracic malignancy or breast cancer
2. Between 18-99 years-old

Exclusion Criteria:

1. Patients with history of radiotherapy
2. Patients with history of atrial fibrillation
3. Patients with pacemaker implantation

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation New Onset

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with Thoracic Malignancies

All patients undergoing RT for Thoracic Malignancies

ECG

Intervention Type DIAGNOSTIC_TEST

12 lead ecg for each participant

Patients with Breast Cancer

All patients undergoing RT for Breast Cancer

ECG

Intervention Type DIAGNOSTIC_TEST

12 lead ecg for each participant

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ECG

12 lead ecg for each participant

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with radiotherapy for thoracic malignancy or breast cancer
* Between 18-99 years-old

Exclusion Criteria

* Patients with history of radiotherapy
* Patients with history of atrial fibrillation
* Patients with pacemaker implantation
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Istanbul University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Cafer Zorkun

Head, Division of CardioOncology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cafer Zorkun, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Faculty member

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Istanbul Faculty of Medicine

Fatih, Istanbul, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COEXIST-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.